Cambrex Reports Fourth Quarter And Full Year 2009 Results
EAST RUTHERFORD, N.J., Feb. 10 /PRNewswire-FirstCall/ -- Cambrex Corporation (NYSE: CBM) reports fourth quarter results for the period ended December 31, 2009.
- Reported sales decreased by 9.9%, and excluding the impact of foreign currency, sales decreased 15.8% compared to fourth quarter 2008. For the full year 2009, reported sales decreased 5.3%, and decreased 1.2% excluding the impact of foreign currency.
- EBITDA was $9.4 million in the fourth quarter 2009 compared to Adjusted EBITDA of $10.5 million in the same quarter last year. For the full year 2009, EBITDA was $47.1 million compared to Adjusted EBITDA of $47.7 million in 2008. See the reconciling table at the end of this release.
- Debt, net of cash was $68.5 million at the end of fourth quarter 2009, a reduction of $10.2 million during the quarter and a reduction of $22.9 million for the year.
- Provision for Income Taxes includes a $5.3 million expense in the fourth quarter 2009 related to an ongoing audit of a European subsidiary.
- Net Loss was $2.8 million in the fourth quarter 2009 compared with $1.0 million for the fourth quarter 2008. Net Income was $10.4 million for the full year 2009 compared to $7.9 million in 2008.
Fourth Quarter 2009 Operating Results
Fourth quarter 2009 sales of $58.7 million were 9.9% lower than the fourth quarter 2008. Excluding a 5.9% favorable impact of foreign exchange, reflecting a weaker U.S. dollar, sales decreased 15.8%. The decrease is primarily due to lower volumes of an active pharmaceutical ingredient ("API") that utilizes the Company's polymeric drug delivery technology, lower sales of two APIs manufactured under long-term supply agreements and lower custom development revenues, all due to the timing of orders throughout 2009. Volumes of a feed additive for which a contract expired earlier in 2009 were also lower. Partially offsetting these decreases were increased generic revenues resulting from improved order patterns.Fourth quarter 2009 Gross Margin increased to 24.7% of sales from 24.2% during the fourth quarter 2008, with foreign currency unfavorably impacting gross margin by 0.6% in the fourth quarter 2009. Cost reductions, and to a lesser extent, positive product mix, were the main drivers of the higher margins. This was partially offset by lower pricing of generic APIs and lower volumes of an API manufactured under a long-term supply agreement.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV